Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs ProShares UltraPro S&P500 — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B), while ProShares UltraPro S&P500 trades at $154.34 (market cap $5.57B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 4.5× ProShares UltraPro S&P500's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while ProShares UltraPro S&P500 pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and ProShares UltraPro S&P500 for 29 Days on average.
| RPRX | UPRO | |
|---|---|---|
Market Cap | $25.27B | $5.57B |
Volume | 3,671,183 | 1,824,096 |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.96 | $157.66 |
52-Week Low | $35.44 | $89.29 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UPRO trades at $155.21, down 0.77% on the day, while maintaining a bullish technical stance with strong moving average support. The stock shows neutral momentum oscillators but benefits from positive market sentiment around S&P 500 exposure. Recent news highlights strong corporate earnings growth expectations of 35% for 2026, though concerns exist about concentration risks in top holdings and potential profit growth slowdown to 15% in 2027.
The outlook remains cautiously optimistic given the S&P 500's historical bullish seasonal patterns and AI-driven earnings growth, though investors face risks from market concentration, elevated valuations, and potential Federal Reserve policy impacts. Wall Street expects continued gains but acknowledges the need for selective positioning amid changing market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
